Metronomic chemotherapy offers hope for children with neuroblastoma
- OPACC
- Jan 29
- 1 min read
Despite advances in treatment, survival rates for high-risk and relapsed/refractory neuroblastoma remain dismal, and options like autologous stem cell transplantation and immunotherapy are frequently unavailable in low- and middle-income countries. Given these stark realities, there is a critical need for alternative, more accessible therapies like metronomic chemotherapy (MC) to improve survival prospects for these children.
Recent Posts
See AllA team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...
Comentários